Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.

The overall CVAE in a group of female patients with breast cancer who had exposure to CDK4/6 inhibitors was slightly higher than for those treated with anthracyclines, with marginal significance (35.9 versus 28.5 per 100 person‐years; P =0.063; Table 2 ); however, there was no statistical difference between these 2 groups in the competing risk analysis (Figure 2A ).

also in 3,113 other papers